Is Standard TRUS-Guided Prostate Biopsy the End of the Game?
TRUS-guided prostate biopsy costs far less than magnetic resonance imaging-targeted biopsy
Is Standard TRUS-Guided Prostate Biopsy the End of the Game?
Prostate cancer (prostate cancer) remains a major cause of morbidity and mortality among men worldwide, and histopathologic tissue sampling plays a pivotal role in diagnosis.
The aim of this study wa to present the clinical outcomes and costs of TRUS-guided prostate biopsy performed in the clinic and to compare its costs with those of magnetic resonance imaging-targeted biopsy.
Data from 221 patients who underwent prostate biopsy were retrospectively analyzed.
at this price, TRUS biopsy costs a fraction of magnetic resonance imaging-targeted biopsy
Prostate cancer was detected in 40.3% (n = 89) of the 221 patients.
Clinically significant prostate cancer was identified in 29.9% (n = 66), whereas malignancy could not be excluded in 1.4% (n = 3).
In contrast, based on data obtained from 9 hospitals, the reported mean cost of magnetic resonance imaging-targeted biopsy was US $1449.
Transrectal ultrasound-guided prostate needle biopsy remains an effectivemand highly cost-efficient diagnostic method in patients with suspected prostate cancer.
This technique may be particularly valuable in clinical settings where access to magnetic resonance imaging-targeted biopsy is limited. Cite this article as: Benli E, Kadim N, Yüce A, Çırakoğlu A, Keleş M, Arslan A.
Is standard TRUS-guided prostate biopsy the end of the game? Urol Res Pract. 2025;51(6): 237-241.